Sanofi (NASDAQ:SNY) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Sanofi has a consensus “Hold” rating from 16 analysts: 10 holds, three buys, two strong buys and one sell. The average 12-month price target is $49.50, above the stock’s reported $42.50 opening price.
• Analyst sentiment is mixed, with Weiss Ratings downgrading Sanofi to “sell,” while Wall Street Zen upgraded it to “buy”; HSBC maintained its “buy” rating and RBC initiated coverage with a “sector perform” rating.
• Sanofi reported quarterly revenue of $13.36 billion, up 16% year over year, and adjusted earnings of $2.41 per share. Institutional investors and hedge funds own approximately 14.03% of the company.

Shares of Sanofi (NASDAQ:SNY - Get Free Report) have received an average recommendation of "Hold" from the sixteen research firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, three have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $49.50.

Several analysts have weighed in on SNY shares. Weiss Ratings downgraded shares of Sanofi from a "hold (c-)" rating to a "sell (d)" rating in a research report on Monday, August 3rd. Morgan Stanley set a $49.00 price target on shares of Sanofi in a report on Wednesday, July 8th. Royal Bank Of Canada began coverage on shares of Sanofi in a report on Tuesday, September 8th. They set a "sector perform" rating on the stock. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 29th. Finally, HSBC restated a "buy" rating on shares of Sanofi in a research note on Thursday, September 10th.

Sanofi Trading Up 0.0%

Shares of NASDAQ:SNY opened at $42.50 on Tuesday. The business's 50-day moving average is $43.89 and its 200 day moving average is $44.36. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68. The firm has a market capitalization of $103.04 billion, a P/E ratio of 22.25, a P/E/G ratio of 1.28 and a beta of 0.35.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported $2.41 earnings per share for the quarter. Sanofi had a return on equity of 14.19% and a net margin of 8.66%.The business had revenue of $13.36 billion during the quarter. During the same period in the prior year, the business posted $3.24 EPS. Sanofi's revenue was up 16.0% compared to the same quarter last year. On average, research analysts predict that Sanofi will post 5.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sanofi

A number of institutional investors and hedge funds have recently modified their holdings of SNY. Assetmark Inc. boosted its holdings in Sanofi by 14.8% in the first quarter. Assetmark Inc. now owns 509,464 shares of the company's stock valued at $24,546,000 after purchasing an additional 65,796 shares during the last quarter. AMG National Trust Bank purchased a new position in shares of Sanofi during the 1st quarter valued at about $2,719,000. Tidal Investments LLC lifted its holdings in shares of Sanofi by 21.5% in the 2nd quarter. Tidal Investments LLC now owns 165,289 shares of the company's stock valued at $7,051,000 after buying an additional 29,283 shares during the period. Manning & Napier Advisors LLC lifted its holdings in shares of Sanofi by 728,134.8% in the 1st quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company's stock valued at $57,542,000 after buying an additional 1,194,141 shares during the period. Finally, Goodman Financial Corp purchased a new stake in shares of Sanofi in the first quarter worth about $9,833,000. Institutional investors and hedge funds own 14.03% of the company's stock.

Sanofi Company Profile

Sanofi is a global healthcare company headquartered in France that develops, manufactures and markets prescription medicines and vaccines. Its portfolio serves patients across areas including immunology, rare diseases, rare blood disorders, neurology, oncology and inflammatory conditions, as well as other specialty-care and general-medicine categories.

The company is also a major vaccine producer through its vaccines business, which supplies products for diseases such as influenza, polio, pertussis, meningitis and dengue.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.